Two Omaha women lost more than 300 lbs. combined with injections of a GLP-1 drug, which are used increasingly for weight loss ...

For years, conventional wisdom has been that weight loss is a matter of willpower. Those who are overweight or obese just need to try harder to eat less and exercise more. But while diet and ...

The new weight loss drug offers promising results for those who are overweight or obese. Learn about how Zepbound works, its ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout ...

WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...

A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic ...

U.S. stock futures were little changed on Thursday night after the major averages slid following a lackluster earnings ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.